fbpx

Tag: national news

Contact Us

Contact us on 1300 369 772 Monday to Friday, business hours

Share this page

PSA set to negotiate and sign new pharmacy programs agreement

31 January 2025

 

The Pharmaceutical Society of Australia (PSA) are set to negotiate the first dedicated agreement on pharmacy programs with the Australian Government. PSA will be signatory to this agreement.

 

The agreement will cover a range of pharmacy programs that no longer sit within the 8th Community Pharmacy Agreement, including but not limited to medication management programs (including Home Medicines Reviews and Residential Medication Management Reviews), Aboriginal and Torres Strait Islander specific programs, and rural support programs that encompass pharmacists in a range of practice areas.

 

The new agreement will see PSA and the Commonwealth work together, alongside other pharmacy stakeholders, to strengthen programs that pharmacists deliver across the health system.

 

PSA National President Associate Professor Fei Sim FPS said the agreement was an opportunity to reform programs to ensure they are fit-for-purpose, now and into the future.

 

“PSA is the recognised peak body for all pharmacists, in all areas of practice across our health system. This agreement is an opportunity to reform program rules and funding arrangements to maximise the impact of pharmacists across the health sector,” Associate Professor Sim said.

 

“In negotiating a standalone agreement with the Australian Government, we are advocating for the changes we have long known need to happen, allowing pharmacists to best serve our communities.

 

“Members will be aware that following PSA’s advocacy, the government confirmed in late 2024 that these programs would have ongoing funding beyond the current financial year. Now that there is security of funding for these programs, our focus turns to removing the barriers that have prevented pharmacists from playing a greater role in patient care.”

 

As signatory to the new agreement, PSA will be seeking feedback from pharmacists and stakeholders on program arrangements and barriers.

 

“I encourage every pharmacist involved in these programs to have their say so that we can provide a full picture of the barriers, challenges and opportunities for pharmacists to provide better care for patients.

 

“PSA looks forward to continuing our work with the federal government to secure a stronger pharmacy profession now and into the future,” Associate Professor Sim concluded.

 

PSA consultant pharmacist adviser Debbie Rigby FPS also welcomed the announcement.

 

“As the home for credentialed pharmacists, it’s important that PSA is the organisation leading these discussions,” Ms Rigby said.

 

“I’m excited to be part of PSA’s team, advocating for improvements to these programs. As someone with a deep understanding of the current programs, I am committed to raising awareness of the benefits of these programs and further enhancing outcomes for patients.”

​

Media contact:   Georgia Clarke   M: 0480 099 798  E: georgia.clarke@psa.org.au

Share this page
Share this page

PSA announce intent to acquire Australasian College of Pharmacy

28 January 2025

 

The Pharmaceutical Society of Australia (PSA) Board has today announced plans to acquire the Australasian College of Pharmacy, further growing PSA’s leadership in education and training for pharmacists, pharmacy assistants, and technicians.

 

The Australasian College of Pharmacy (the College) is a member-based organisation developing and delivering education, training, and research programs to pharmacists and pharmacy assistants since 1976.

 

The decision to acquire the College is part of the PSA Board’s broader plan to maximise member value through growth, expanding education opportunities for the profession, and securing a long-term, sustainable future for PSA as the premier training and education provider for pharmacists, pharmacy assistants and technicians.

 

PSA’s acquisition of the College builds on its long history of high-quality, nation-leading education and training for pharmacists, allowing further investment in professional and practice support for members.

 

The PSA Board has carefully considered the impact of acquiring the College, and alongside independent advice from third-party experts the Board is confident this is the right path forward for PSA, its members, and the broader profession.

 

National President and Chair of the PSA Board Associate Professor Fei Sim FPS said the acquisition will be a transformational opportunity to grow PSA’s industry-leading education and workforce development offer.

 

“The PSA Board’s strategic decision to acquire the Australasian College of Pharmacy secures a long-term future for pharmacy workforce education. It puts PSA in a stronger representative and financial position to support and advocate for our members during this pivotal time of practice change in pharmacy,” Associate Professor Sim said.

 

“Along with the PSA Board, I fully understand the challenges pharmacists are facing, as we transition to full scope of practice and our roles become increasingly demanding.

Growing our footprint within pharmacy education means we can further invest in not only education, but also the professional and practice support PSA provides. As our profession continues to mature, this unity will provide the necessary strength our profession needs at this critical time of change to fully utilise our skills and expertise.

 

“We are ambitious about our future growth as an organisation, as the peak education and representative body for all pharmacists across all areas of practice.

 

“We look forward to being able to provide even more education opportunities and support to pharmacists, pharmacy assistants and technicians, strengthening our pharmacy profession and ultimately improving care for our patients,” Associate Professor Sim concluded.

 

ACP Chief Executive Officer Amanda Seeto said the College and the PSA had always shared a commitment to providing contemporary education and training in a format that is accessible, efficient, and most importantly – highly relevant to Australian pharmacists.

 

“This exciting and pragmatic change maximises the focus on world-leading professional development for Australian pharmacists, no matter their practice setting or career stage.

 

“The move will set our sector up for success, at a time when pharmacy is becoming an increasingly valued frontline health service.”

 

PSA members are set to vote on matters relating to the acquisition at an upcoming meeting.

 

​

Media contact:   Georgia Clarke   M: 0480 099 798  E: georgia.clarke@psa.org.au

Share this page
Share this page

PSA-credentialed pharmacists gain new official post-nominals

2 December 2024

 

The Pharmaceutical Society of Australia (PSA) today announces new professional post-nominals for members who have achieved Medication Management Review (MMR) and Aged Care Onsite Pharmacist (ACOP) credentials through PSA training programs.

 

PSA is committed to elevating professional practice and ensuring pharmacists are recognised for their additional skills and qualifications. The new post nominals enable members to display their advanced practice credentials in a way that validates their expertise and commitment to high-quality patient care.

 

Credentialed pharmacist post-nominals provide visible acknowledgement of the advanced clinical skills and area of specialisation, enabling pharmacists to be readily recognised as key players in multidisciplinary teams.

 

Post-nominals are linked to the members current PSA postnominal MPS or FPS, followed by CredPharm with the appropriate credentials in brackets. For example, a PSA Fellow who has achieved their MMR credential would use post nominals FPS CredPharm (MMR).

 

PSA’s Consultant Pharmacists Community of Speciality Interest Chair Deborah Hawthorne FPS CredPharm (MMR) is excited that members are now able to have their credentials recognised through the addition of post nominals.

 

“Our credentialed pharmacist workforce is a really passionate and skilled group of professionals. It’s critical for them to be able to have their expertise recognised by all members of the care team, Ms Hawthorne said.

 

“It’s also important that they’re easily recognisable to consumers – we’ve done a lot of advocacy work with consumer groups recently and for them to have a way of knowing that their pharmacist is qualified and part of a practice community that drives innovation and career-long learning is essential.

 

“These post nominals will go a long way to driving public trust and confidence in our credentialed pharmacist workforce,” Ms Hawthorne concluded.

 

PSA National President Associate Professor Fei Sim FPS said the recognition of PSA’s credentialed pharmacist members through post nominals is the next logical step in support for credentialed pharmacists.

 

“PSA is the home for credentialed pharmacists, as the only organisation with a track record of consistent support, training and advocacy for credentialed pharmacists across all areas of practice.

 

“We have a long and proud history of advocating for credentialed pharmacists and are focused on how we can continue growing and supporting this workforce.

 

“PSA is committed to supporting credentialed pharmacists in a way unmatched by any other organisation at present. I am proud that PSA continues to be the home for credentialed pharmacists,” Associate Professor Sim said.

​

Media contact:   Georgia Clarke   M: 0480 099 798  E: georgia.clarke@psa.org.au

Share this page
Share this page

Empowering pharmacists to meet Australia’s health needs

25 September 2024

Marking World Pharmacists Day today (25 September), Australia’s peak body for pharmacists the Pharmaceutical Society of Australia (PSA) reaffirms the key actions that form its flagship vision Pharmacists in 2030, highlighting the growing role of Australia’s pharmacists in meeting health needs.

 

Pharmacists around Australia and the world are responding to health challenges every day. Whether this be improving access to essential medicines, vaccination services and health advice, or optimising medicine use for safety and efficacy, pharmacists are on the frontlines of Australia’s health care system every day.

 

Last month PSA released Pharmacists in 2030, mapping the direction of the pharmacy profession over the coming years. Pharmacists in 2030 further identifies the key areas for reform in both practice and workforce development necessary to meet the health challenges of the future.

 

Pharmacists in 2030 continues a strong focus on medicine safety and improving access to care and medicines, also building an increased focus on patient equity, sustainability and supports which empower pharmacists to be the best they can be.

 

PSA National President Associate Professor Fei Sim FPS said that the future PSA sees further harnesses the potential of pharmacists.

 

“Australians need the expertise of pharmacists more than ever before,” Associate Professor Sim said. “As medicine use continues to grow and our population ages, Australian health needs are becoming more complex.”

 

“PSA sees pharmacists in all areas of practice doing more to meet these health challenges, and supported to do more for their patients or the communities they serve.

 

“By 2030, we see community pharmacy formally recognised as a preventive and primary health care hub where pharmacists are appropriately funded to practise to full and top of scope and play a greater role in preventive health care, treatment of acute illnesses and management of chronic health conditions – particularly through an increased prescribing role.

 

“While most community pharmacies will remain broad in their health offering to the community, some will become more specialised and focused to meet specific needs.

 

“Many of these changes are already well underway with various scope of practice pilots and changes occurring in every state and territory. These innovations and initiatives have been driven by real patient need and health system demand.

 

“We also see the need for pharmacists wherever medicines are prescribed, dispensed, administered or reviewed. This means playing a bigger role in multidisciplinary health care teams.

 

“Some of these roles will be relevant to community pharmacists, particularly in outreach services, others will see pharmacists embedded in these teams, often being a key conduit to reduce medicine safety risks in liaison with a patient’s community pharmacy.

 

“To the 38,000 pharmacists practising around the country, make sure you take a moment to celebrate your contribution to the health and wellbeing of your community this World Pharmacy Week and particularly today on World Pharmacists Day. On behalf of PSA, thank you for all that you do,” Associate Professor Sim concluded.

 

​

Media contact:   Georgia Clarke   M: 0480 099 798  E: georgia.clarke@psa.org.au

Share this page
Share this page

MRNs extended for credentialing transition

The Pharmaceutical Society of Australia (PSA) welcomes the extension of Medication Review Numbers (MRNs) to support credentialed pharmacists to continue providing MMR services during the transition to a new credentialing system.

​

The extension was announced today by the Department of Health and Aged Care Assistant Secretary – Pharmacy Branch, David Laffan, in an email to credentialed pharmacists. The move gives pharmacists 12 months to transition to a new credential, including a Medication Management Review (MMR) credential, and an Aged Care credential.

​

PSA is set to offer both MMR and Aged Care credentials, as well as offer a pathway for recognition of prior learning to recognise the experience of practising credentialed pharmacists in line with the Accreditation Standards for MMR and Aged Care On-site Pharmacist education programs | Australian Pharmacy Council.

​

PSA National President Associate Professor Fei Sim FPS said that PSA’s priority and commitment to workforce development have not changed.

​

“We have been in discussions with the Department for some time to ensure that transition arrangements are in place to minimise disruption to patient services and allow the existing workforce to continue providing MMR services in the immediate term.

​

“I’m pleased to see action from the Department to allow these services to continue.

​

A/Prof Sim said that PSA’s credentialing program, which is pending accreditation with the Australian Pharmacy Council, is set to feature ongoing support for credentialed pharmacists and those seeking credentials.

​

“PSA continues to approach this fast-moving practice area with the intent to support our workforce, and to ensure that the credentialing and recredentialing process is achievable and affordable.

“All pharmacists who have already undergone credentialing will be able to apply for PSA’s recognition of prior learning as part of the new credentialing process.

​

“PSA is proud to offer further support to members, including offering the new MMR credential to currently credentialed pharmacists with recognition of prior learning at no cost for Professional Plus members.

​

“This is part of our ongoing support for this workforce, solidifying our place as the home for credentialed pharmacists.”

​

​

​

Media contact:   Georgia Clarke   M: 0480 099 798  E: georgia.clarke@psa.org.au

Share this page
Share this page

National access to vaccines must be a priority

30 November 2023

 

The Pharmaceutical Society of Australia (PSA) is again calling for vaccines to be made accessible to more Australians by fully utilising pharmacists as part of the immunisation workforce, following a new report from Australian think tank Grattan Institute.

​

The Grattan Institute report A fair shot: How to close the vaccination gap specifically recommends action on a National Vaccines Partnership Agreement and harmonisation of the state-based regulations that determine pharmacists’ authority to deliver certain vaccines.

​

The report also calls for new funding for Primary Health Networks (PHNs) to support general practice, pharmacists, and aged care providers to promote vaccination in mainstream primary care.

​

PSA National President Dr Fei Sim FPS welcomes the Grattan Institute’s recommendations, which echo PSA’s calls for nationally consistent vaccination authorities.

​

“The Grattan Institute’s report is a stark look at how far we still have to go to make vaccination equitable for all Australians,” Dr Sim says.

​

“We know that there is no one-size-fits-all approach to improving vaccine uptake, with the report rightly highlighting the need for a tailored approach to ensuring vulnerable cohorts don’t fall through the cracks.

​

“The Federal Government’s move to open up National Immunisation Program funding for pharmacist-administered vaccines is a welcome first step, but there is more work to be done to allow pharmacists to deliver all vaccines to patients of all ages.

​

“At the moment, every jurisdiction in Australia has different regulations around which vaccinations can be administered by pharmacists.

​

“A nationally consistent schedule of pharmacist-administered vaccines is key to achieve equitable access to government-funded vaccines by all Australians.

​

“Pharmacists can and should be utilised as trusted health care professionals, working hand in glove with the rest of the primary care team to break down the barriers to vaccination, from improving equity and access, to amplifying public health messages.

​

“Our health system needs all immunisers to play a role in delivering vaccines wherever there is a patient need, whether a GP, nurse practitioner or pharmacist,” Dr Sim concluded.

​

The Grattan Institute’s A fair shot: How to close the vaccination gap report is available here.

​

​

​

Media contact:   Georgia Clarke   M: 0480 099 798  E: georgia.clarke@psa.org.au

Share this page
Share this page

Improve Quality Use of Medicines to improve mental health care: report

22 November 2023

 

Pharmacists can play a greater role in helping patients manage their mental health through the quality use of medicines, a new report from the Pharmaceutical Society of Australia (PSA) has found.  

 

The sixth edition of PSA’s flagship Medicine Safety series, Medicine Safety: Mental Health Care report highlights opportunities for pharmacists to better support Australians using medicines to treat mental health conditions, including improving access to care and investing in quality use of medicines services at critical points of care.  

 

Key report stats: 

 

  • People with severe mental health conditions have poorer physical health than the general community and have a 12–16 year shorter life expectancy. 
  • 18% of Australians use medicines to treat a mental health condition.  
  • Antidepressants were involved in 31% of medicine-related deaths due to overdose, and antipsychotics in 17% of medicine-related deaths due to overdose. 
  • 1 in 4 Australians are taking a medicine that would not be recommended for them based on the individual genetic variation of their drug metabolising enzymes. 
  • Medicine changes are frequent in mental health facilities, with an average of 10 changes per admission.  
  • Over 40% of mental health facilities do not have any pharmaceutical handover at discharge. 

 

PSA’s recommendations from the Medicine Safety: Mental Health Care report support better medicine management and wrap-around mental health care to improve quality of life for Australians living with a mental health condition. 

 

Quotes attributable to PSA National President Dr Fei Sim FPS:

 

“The evidence presented in this report shows that, as a nation, we need to do better.

 

“Wherever medicines are used there is a risk of medicine misadventure, which is exactly what this report has found.   

 

“We know that the prevalence of mental ill health is on the rise, and more people are using medicines to manage a mental health condition.  

 

“Too often we hear of people stopping treatment altogether because of the effects of these medicines, because they make them unwell. This is where we believe there is significant opportunity for investment in pharmacist services to help support the safe and effective use of medicines.

 

“People using medicines in their mental health care need better access to the expertise of pharmacists at all stages of management – in hospitals, in community pharmacies, in private clinics and across the whole spectrum of care.  

 

“Our recommendations focus on addressing specific gaps in the provision of comprehensive health care and challenge the ‘set-and-forget’ paradigm that people using mental health medicines too often experience.  

 

“From implementing a mental health screening program in community pharmacies, to formalising transition of care pharmacist services to reduce the risk of medicine-related harm when transferring from hospital to home, pharmacists can and should be part of a collaborative, multidisciplinary and person-centred approach to mental health care. 

 

“This is about ensuring patients have the support they need to get the most out of their medicines safely and effectively.

 

Quotes attributable to Assistant Minister for Mental Health and Suicide Prevention and Assistant Minister for Rural and Regional Health, Emma McBride MP:

 

“The Pharmaceutical Society of Australia (PSA) should be commended on the launch of their most recent medicine safety report, Medicine Safety: Mental Health Care.

 

“This is a timely report on the importance of medication safety in mental health given the prevalence of common mental health disorders and the medications often prescribed as part of treatment and care.

 

“The report also highlights the vital role pharmacists play – across settings – to improve safety and importantly reduce harm.

 

“As a pharmacist who worked in acute adult inpatient services I know this report will be influential as we work together to improve patient care.”

 

The Medicine Safety: Mental Health Care report and PSA’s recommendations are available at https://www.psa.org.au/advocacy/working-for-our-profession/medicine-safety/mental_health/  

 

 

Media contact:   Georgia Clarke   M: 0480 099 798  E: georgia.clarke@psa.org.au 

Share this page
Share this page

Quality Use of Medicines Alliance funded to promote health literacy

9 October 2023

 

Two new grants to support consumer health literacy and improve the use of medicines will see peak health and consumer organisations working side-by-side.

 

The Quality Use of Medicines Alliance represents a group of eight health and consumer organisations, bringing together unique expertise from education providers, consumer groups, researchers, health professionals, peak bodies and member organisations to develop free health education products for a national audience of health professionals and consumers.

 

The grants will run over a 2-year period and address priority quality use of medicines issues for atopic dermatitis, gout, antidepressants in older people and oral anticoagulants, awarded under the Australian Government’s Quality Use of Diagnostics, Therapeutics and Pathology (QUDTP) Program.

 

Pharmaceutical Society of Australia (PSA) National President Dr Fei Sim FPS said that improving the Quality Use of Medicines requires all health professionals working together.

 

“PSA is proud to be part of the Quality Use of Medicines Alliance, awarded health professional education and consumer health literacy grants by the Department of Health and Aged Care to improve health literacy and education,” Dr Sim said.

 

“Evidence shows that when health professionals and consumers work together, we can support more effective healthcare, better medicine safety and improved health outcomes.

 

“We are working with the Quality Use of Medicines Alliance to close knowledge gaps in atopic dermatitis, gout, oral anticoagulants, and antidepressants in older people.

 

“Through this work, PSA is proudly supporting pharmacists to not only champion safe and effective medicine use, but also to support health literacy and information for our patients.”

 

The Quality Use of Medicines Alliance consists of:

 

  • Medcast: a nationwide provider of independent education for a range of health professions
  • Health Care Consumers’ Association: a peak health consumer organisation working to improve the quality and safety of health care
  • Arthritis Australia: the leading national arthritis charity supporting people living with all types of arthritis
  • Eczema Support Australia: a national support network advocating for people living with eczema
  • Pharmaceutical Society of Australia: the national peak professional pharmacy body representing Australia’s 36,000 pharmacists across all sectors and specialisations
  • QUM Connect: a specialist consultancy with experience and expertise in creating and implementing quality use of medicines initiatives to improve health outcomes
  • Royal Australian College of General Practitioners: Australia’s largest professional general practice organisation responsible for maintaining standards for quality clinical practice, education and training, and research in Australian general practice
  • Wiser Healthcare: a research collaboration involving the University of Sydney, Bond University, Monash University and the University of Wollongong, with a special interest in research in the areas of rational test ordering and quality use of medicines.

 

 

Media contact:   Georgia Clarke   M: 0480 099 798  E: georgia.clarke@psa.org.au

 

Share this page
Share this page

3,000 lives saved in first year of Take-Home Naloxone program

31 August 2023

 

This International Overdose Awareness Day, the Pharmaceutical Society of Australia (PSA) recognises the important role pharmacists play in supporting patients taking prescription opioids, noting that in its first year alone, the Take Home Naloxone (THN) program has saved 3000 lives.

 

The national THN program provides naloxone to anyone who may experience, or witness, an opioid overdose or adverse reaction for free and without a prescription.

 

Since the THN program began on 1 July 2022, an estimated 3,000 doses have been used by Australians experiencing or witnessing an opioid overdose or adverse reaction equating to 8 uses per day.

 

PSA National President Dr Fei Sim FPS says that pharmacists have been key to the success of the program because of their accessibility and expertise.

 

“The Take Home Naloxone program has saved Australian lives,” Dr Sim said.

 

“Evidence from the first year of the THN program shows that pharmacists are well-placed to provide naloxone, whether alongside a prescribed opioid or as a stand-alone supply.

 

“As our most accessible healthcare professionals, pharmacists have distributed over 90% of naloxone for the THN Program. This is evidence that pharmacist-provided naloxone as one of the harm minimisation initiatives, alongside counselling, is feasible and acceptable by Australians.

 

“To ensure ongoing sustainability and impact, pharmacists must be empowered and supported to provide this life-saving service.

 

“We are urging anyone taking opioids for pain management, or caring for someone who does, to have a conversation with your local pharmacist about having naloxone on-hand. We can also provide advice about identifying an opioid overdose and how to respond during an emergency.

 

“Over recent years we have seen more cases of illicit party drugs being spiked with acetyl-fentanyl which can cause opioid overdoses even in small amounts.

 

“Your pharmacist is there to provide judgement-free, expert advice on when and how to use this life-saving drug.

 

“It could save your life, or the life of a friend.”

 

Take Home Naloxone is available to Australians through their local pharmacist. PSA recommends calling ahead to ensure your local pharmacy participates in the THN program and has available stock.

 

Key facts:

  • Up to 8 lives saved each day from use of Take-Home Naloxone
  • Over 110,000 Australians are currently struggling with opioid dependence
  • 7% of unintentional drug-induced deaths in 2021 involved opioids

 

 

Media contact:   Georgia Clarke   M: 0480 099 798  E: georgia.clarke@psa.org.au

 

Data from 1 July 2022 to 30 June 2023, provided by the Department of Health and Aged Care.

Penington Institute Australia Annual Overdose Report 2023

Share this page
Share this page

Pharmacists can deliver on current and future challenges

25 August 2023

 

Following the release of the Australian Government’s Intergenerational Report 2023, the Pharmaceutical Society of Australia (PSA) has called for pharmacists to be able to do more to support the country’s increased healthcare needs as our population ages.

 

The report, released yesterday, highlights five major factors affecting public policy moving forward. In particular, the report acknowledges that Australia’s ageing population and rising demand for care and support services will add further pressure on our already strained health system, hospital emergency departments, and further exacerbate wait times in General Practice.

 

PSA National President Dr Fei Sim FPS said the report highlighted both the urgent and the long-term need for pharmacists in all practice areas to work to their top of scope.

 

“The Federal Government’s Intergenerational Report confirmed that our gaining population will continue to have a significant impact on the Australian economy,” she said.

 

“Combined with the rising demand for quality health care services, we must be able to ensure the long-term sustainability of our health system.

 

“Access to care is a growing issue in Australia, and the situation is exacerbated in rural and remote communities.

 

“Australians need all health professionals working to their top of scope – including pharmacists.”

 

The Federal Government also announced yesterday that ANU’s Professor Mark Cormack will lead the Unleashing the Potential of our Health Workforce Review, to be delivered in 2024.

 

“The government’s scope of practice review needs to heed the warnings of the Intergenerational report and unlock the potential of our health workforce using pharmacists,” Dr Sim said.

 

“Pharmacists are highly trained health professionals and should be supported to practise to full scope, contributing to sustainability of our health system to enable equitable access to healthcare by all Australians.

 

“There are a range of common ailments which can be safely and effectively managed by pharmacists, supported by international evidence, facilitating safe and timely care.

 

“This can only be achieved with meaningful investment and funding to empower pharmacists to deliver important health care to Australians.

 

“Pharmacists can, and should, play a significant role to improve Australian’s access to care, and contribute towards quality, safe and effective use of medicines in all parts of the healthcare system.

 

“On behalf of Australian pharmacists, I look forward to working with Professor Cormack and his team on the Unleashing the Potential of our Health Workforce Review,” Dr Sim concluded.

 

The Federal Government’s Intergenerational Report is available here.

 

 

Media contact:   Georgia Clarke   M: 0480 099 798  E: georgia.clarke@psa.org.au

Share this page

In the spirit of reconciliation, the Pharmaceutical Society of Australia (PSA) acknowledges the Traditional Custodians of Country throughout Australia and their connections to land, sea and community. We pay our respect to their Elders past and present and extend that respect to all Aboriginal and Torres Strait Islander peoples today. We recognise that Aboriginal and Torres Strait Islander peoples were our first pharmacists.

CONTACT US | TERMS OF USE | PRIVACY

© 2025 Pharmaceutical Society of Australia Ltd. All rights reserved.